Agilent Technologies Inc. announced the EU launch of a new CE-IVD labeled IQFISH lung cancer panel for automated analysis on Dako Omnis. The new panel enables routine pathology laboratories to easily integrate fast, high-quality fluorescence in situ hybridization (FISH) into their immunohistochemical (IHC) workflow. This allows labs to simultaneously stain IHC and FISH slides and enable multiple FISH slides to be processed in just four hours, a process that often takes two days or more with traditional FISH.
The new panel, comprising of ALK, ROS1, RET and MET IQFISH probes, was designed using the groundbreaking, oligonucleotide-based SureFISH technology utilizing formamide-free IQFISH fast hybridization buffer.
“We are excited about the upcoming probe launches for Dako Omnis,” said Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group. “Agilent is committed to improving the speed and accuracy of patient-sample processing and the quality of test performance. We know that these factors greatly affect treatment decisions and patient outcome.”
The lung cancer panel is the second IQFISH launch for Dako Omnis following its introduction of HER2 IQFISH pharmDx in 2015.
About Agilent Technologies
Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenue of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.
(Source: Business Wire)
